BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scaldaferri F, Lancellotti S, Pizzoferrato M, Cristofaro RD. Haemostatic system in inflammatory bowel diseases: New players in gut inflammation. World J Gastroenterol 2011; 17(5): 594-608 [PMID: 21350708 DOI: 10.3748/wjg.v17.i5.594] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Wu P, Jia F, Zhang B, Zhang P. Risk of cardiovascular disease in inflammatory bowel disease. Exp Ther Med 2017;13:395-400. [PMID: 28352306 DOI: 10.3892/etm.2016.3966] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
2 Marcos-Ramiro B, García-Weber D, Barroso S, Feito J, Ortega MC, Cernuda-Morollón E, Reglero-Real N, Fernández-Martín L, Durán MC, Alonso MA, Correas I, Cox S, Ridley AJ, Millán J. RhoB controls endothelial barrier recovery by inhibiting Rac1 trafficking to the cell border. J Cell Biol 2016;213:385-402. [PMID: 27138256 DOI: 10.1083/jcb.201504038] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
3 Moukalled NM, Hashash JG, Taher AT. Inflammatory Bowel Disease: An Indication to Screen for Thrombophilia? Diseases 2022;10:14. [DOI: 10.3390/diseases10010014] [Reference Citation Analysis]
4 Jain U, Otley AR, Van Limbergen J, Stadnyk AW. The Complement System in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2014;20:1628-37. [DOI: 10.1097/mib.0000000000000056] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
5 Kayahan H, Sari I, Cullu N, Yuksel F, Demir S, Akarsu M, Goktay Y, Unsal B, Akpinar H. Evaluation of early atherosclerosis in patients with inflammatory bowel disease. Dig Dis Sci. 2012;57:2137-2143. [PMID: 22466100 DOI: 10.1007/s10620-012-2148-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
6 Kraiem I, Hadhri S, Ben Rejeb M, Ifa L, Jmaa A, Ajmi S, Skouri H. Antiphospholipid Antibodies and Procoagulant Profile in Tunisians With Inflammatory Bowel Diseases. Clin Appl Thromb Hemost 2016;22:734-42. [PMID: 25878173 DOI: 10.1177/1076029615581364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
7 Higgins PD, Skup M, Mulani PM, Lin J, Chao J. Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13:316-321. [PMID: 25038374 DOI: 10.1016/j.cgh.2014.07.017] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
8 Schmid W, Vogelsang H, Papay P, Primas C, Eser A, Gratzer C, Handler M, Novacek G, Panzer S. Increased responsiveness to thrombin through protease-activated receptors (PAR)-1 and -4 in active Crohn's disease. Journal of Crohn's and Colitis 2014;8:495-503. [DOI: 10.1016/j.crohns.2013.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
9 Schicho R, Marsche G, Storr M. Cardiovascular complications in inflammatory bowel disease. Curr Drug Targets. 2015;16:181-188. [PMID: 25642719 DOI: 10.2174/1389450116666150202161500] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
10 Arora Z, Wu X, Navaneethan U, Shen B. Non-surgical porto-mesenteric vein thrombosis is associated with worse long-term outcomes in inflammatory bowel diseases. Gastroenterol Rep (Oxf) 2016;4:210-5. [PMID: 25922204 DOI: 10.1093/gastro/gov012] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
11 Motta JP, Palese S, Giorgio C, Chapman K, Denadai-Souza A, Rousset P, Sagnat D, Guiraud L, Edir A, Seguy C, Alric L, Bonnet D, Bournet B, Buscail L, Gilletta C, Buret AG, Wallace JL, Hollenberg MD, Oswald E, Barocelli E, Le Grand S, Le Grand B, Deraison C, Vergnolle N. Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation. J Crohns Colitis 2021;15:787-99. [PMID: 33201214 DOI: 10.1093/ecco-jcc/jjaa229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Schicho R, Marsche G, Storr M. Cardiovascular complications in inflammatory bowel disease. Curr Drug Targets. 2015;16:181-188. [PMID: 25642719 DOI: 10.2174/138945011666650202161500] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Danese S. What’s hot in inflammatory bowel disease in 2011? World J Gastroenterol 2011; 17(5): 545-546 [PMID: 21350702 DOI: 10.3748/wjg.v17.i5.545] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
14 Cibor D, Domagala-Rodacka R, Rodacki T, Jurczyszyn A, Mach T, Owczarek D. Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications. World J Gastroenterol 2016; 22(3): 1067-1077 [PMID: 26811647 DOI: 10.3748/wjg.v22.i3.1067] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
15 Bunu DM, Timofte CE, Ciocoiu M, Floria M, Tarniceriu CC, Barboi OB, Tanase DM. Cardiovascular Manifestations of Inflammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies. Gastroenterol Res Pract 2019;2019:3012509. [PMID: 30733802 DOI: 10.1155/2019/3012509] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 8.7] [Reference Citation Analysis]
16 Owczarek D, Cibor D, Głowacki MK, Rodacki T, Mach T. Inflammatory bowel disease: Epidemiology, pathology and risk factors for hypercoagulability. World J Gastroenterol 2014; 20(1): 53-63 [PMID: 24415858 DOI: 10.3748/wjg.v20.i1.53] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
17 Voudoukis E, Karmiris K, Koutroubakis IE. Multipotent role of platelets in inflammatory bowel diseases: A clinical approach. World J Gastroenterol 2014; 20(12): 3180-3190 [PMID: 24696603 DOI: 10.3748/wjg.v20.i12.3180] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
18 Gravina AG, Dallio M, Masarone M, Rosato V, Aglitti A, Persico M, Loguercio C, Federico A. Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets. Oxid Med Cell Longev 2018;2018:2568569. [PMID: 29849875 DOI: 10.1155/2018/2568569] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
19 Zezos P, Kouklakis G, Saibil F. Inflammatory bowel disease and thromboembolism. World J Gastroenterol 2014; 20(38): 13863-13878 [PMID: 25320522 DOI: 10.3748/wjg.v20.i38.13863] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 53] [Article Influence: 9.5] [Reference Citation Analysis]
20 Thachil J. Lessons learnt from COVID-19 coagulopathy. EJHaem 2021. [PMID: 34226900 DOI: 10.1002/jha2.228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Giannotta M, Tapete G, Emmi G, Silvestri E, Milla M. Thrombosis in inflammatory bowel diseases: what's the link? Thromb J. 2015;13:14. [PMID: 25866483 DOI: 10.1186/s12959-015-0044-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 7.7] [Reference Citation Analysis]
22 Pezold M, Pergamo M, Rockman C, Lugo J. Presentation and Management of Arterial Thromboembolisms during Active Inflammatory Bowel Disease: Case Series and Literature Review. Ann Vasc Surg 2020;67:532-541.e3. [PMID: 32220617 DOI: 10.1016/j.avsg.2020.02.025] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Xu S, Xu ZX, Yan S, Le J, Chen H, Ming L, Xu SG, Lin T. Curcumin suppresses intestinal microvascular endothelial cells invasion and angiogenesis induced by activated platelets. Exp Ther Med 2019;18:1099-106. [PMID: 31316605 DOI: 10.3892/etm.2019.7662] [Reference Citation Analysis]
24 Derkacz A, Olczyk P, Komosinska-Vassev K. Diagnostic Markers for Nonspecific Inflammatory Bowel Diseases. Dis Markers. 2018;2018:7451946. [PMID: 29991970 DOI: 10.1155/2018/7451946] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
25 Violi NV, Schoepfer AM, Fournier N, Guiu B, Bize P, Denys A; for the Swiss Inflammatory Bowel Disease Cohort Study Group. Prevalence and Clinical Importance of Mesenteric Venous Thrombosis in the Swiss Inflammatory Bowel Disease Cohort. American Journal of Roentgenology 2014;203:62-9. [DOI: 10.2214/ajr.13.12447] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
26 Magro F, Soares JB, Fernandes D. Venous thrombosis and prothrombotic factors in inflammatory bowel disease. World J Gastroenterol 2014; 20(17): 4857-4872 [PMID: 24803797 DOI: 10.3748/wjg.v20.i17.4857] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
27 Katsanos A, Asproudis I, Katsanos KH, Dastiridou AI, Aspiotis M, Tsianos EV. Orbital and optic nerve complications of inflammatory bowel disease. J Crohns Colitis. 2013;7:683-693. [PMID: 23083697 DOI: 10.1016/j.crohns.2012.09.020] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
28 Gawrońska B, Matowicka-Karna J, Kralisz M, Kemona H. Markers of inflammation and influence of nitric oxide on platelet activation in the course of ulcerative colitis. Oncotarget 2017;8:68108-14. [PMID: 28978100 DOI: 10.18632/oncotarget.19202] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
29 Tan VP, Chung A, Yan BP, Gibson PR. Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol. 2013;28:1095-1113. [PMID: 23662785 DOI: 10.1111/jgh.12260] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
30 Merker M, Eichler S, Herrmann AM, Wiendl H, Kleinschnitz C, Göbel K, Meuth SG. Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis. J Neuroimmunol 2017;313:125-8. [PMID: 28992973 DOI: 10.1016/j.jneuroim.2017.08.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ruskovska T, Massaro M, Carluccio MA, Arola-Arnal A, Muguerza B, Vanden Berghe W, Declerck K, Bravo FI, Calabriso N, Combet E, Gibney ER, Gomes A, Gonthier MP, Kistanova E, Krga I, Mena P, Morand C, Nunes Dos Santos C, de Pascual-Teresa S, Rodriguez-Mateos A, Scoditti E, Suárez M, Milenkovic D. Systematic bioinformatic analysis of nutrigenomic data of flavanols in cell models of cardiometabolic disease. Food Funct 2020;11:5040-64. [PMID: 32537624 DOI: 10.1039/d0fo00701c] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]